stockrow
Saturday 7 November 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.
- Revenue
- +287.2%
- EPS
- +31.3%
- Free cash flow
- +105.9%
Quarter to September 2026, against a year earlier
4.09
0.42
−9.31%
Follow ALGS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
42.14 | 16.43 | 1.91 | 1.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.24) | (3.34) | (2.41) | 40.59 | |
P/B ratio |
1.72 | 2.43 | 1.89 | 5.21 | |
Price to Tangible BV |
1.72 | 2.43 | 1.89 | 5.21 | |
EV/Sales |
6.54 | 4.75 | 0.95 | 0.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.17) | (0.26) | (0.32) | (0.42) | |
EV/FCF |
(0.17) | (0.26) | (0.32) | (0.42) | |
Quick Ratio |
3.67 | 2.36 | 2.05 | 0.00 | |
Current Ratio |
3.90 | 2.56 | 2.19 | 1.77 | |
Net Debt/EBITDA |
3.33 | 2.04 | 17.82 | — | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.31 | 0.43 | |
Operating CF/Net income |
1.09 | 1.00 | 16.59 | (0.07) | |
Capex/Depreciation |
0.06 | 0.95 | (0.01) | — | |
Research and Development Expense of Revenue |
10,081.66% | 825.16% | 86.58% | 658.49% | |
Selling, General and Administrative Expense of Revenue |
2,926.04% | 226.40% | 20.22% | 204.50% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
862.72% | 46.43% | 4.91% | 44.68% | |
Graham Net Nets |
0.52 | 0.35 | 0.46 | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.59%) | (116.96%) | (126.52%) | (112.79%) | |
Free Cash Flow Yield |
(90.03%) | (110.21%) | (157.05%) | (116.68%) | |
Revenue per Share |
0.02 | 0.27 | 2.66 | 0.27 | |
Operating CF per Share |
(2.20) | (2.22) | (2.39) | 0.14 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.21) | (2.23) | (2.39) | 0.14 | |
Cash per Share |
7.89 | 5.29 | 2.92 | 0.00 | |
Shareholders Equity per Share |
5.42 | 3.06 | 3.06 | 1.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.42 | 3.06 | 3.06 | 1.08 | |
Free Cash Flow |
(21.84) | (23.20) | (24.95) | 1.45 | |
Working Capital |
61.63 | 36.31 | 33.78 | 15.08 | |
Capital Expenditures |
(0.09) | (0.07) | 0.00 | — | |
Net Current Asset Value |
47.87 | 26.86 | 27.68 | (1.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.54 | 0.02 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.28 | 6.05 | 5.18 | 3.93 | |
Average Assets |
79.31 | 107.63 | 100.52 | 78.48 | |
Average Common Equity |
12.29 | 74.12 | 66.87 | 41.57 |
Columns are period end dates · fundamentals updated 6 Nov 2026